SOX9 has distinct roles in the formation and progression of different non‐small cell lung cancer histotypes by Bao, Jie et al.
SOX9 has distinct roles in the formation and progression of different
non-small cell lung cancer histotypes
Jie Bao1 , Katja Närhi1,2, Ana Teodòsio3, Annabrita Hemmes1, Nora M Linnavirta1, Mikko I Mäyränpää4,5 ,
Kaisa Salmenkivi5, John Le Quesne3,6 and Emmy W Verschuren1*
1 Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland
2 GlaxoSmithKline, Espoo, Finland
3 MRC Toxicology Unit, University of Cambridge, Cambridge, UK
4 HUSLAB, Division of Pathology, Helsinki University Hospital, Helsinki, Finland
5 Department of Pathology, University of Helsinki, Helsinki, Finland
6 Leicester Cancer Research Centre, University of Leicester, Leicester, UK
*Correspondence to: EW Verschuren, Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki,
Tukholmankatu 8, 00290 Helsinki, Finland. E-mail: emmy.verschuren@helsinki.fi
Abstract
The transcription factor SOX9 is a key regulator of multiple developmental processes and is frequently re-expressed
in non-small cell lung cancer (NSCLC). Its precise role in the progression of NSCLC histotypes has, however, remained
elusive. We show that SOX9 expression relates to poor overall survival and invasive histopathology in human non-
mucinous adenocarcinoma and is absent in murine early minimally invasive and low in human in situ adenocarci-
noma. Interestingly, despite wide SOX9 expression across advanced NSCLC histotypes, its genetic deletion in the
murine KrasG12D;Lkb1fl/fl model selectively disrupted only the growth of papillary NSCLC, without affecting the ini-
tiation of precursor lesions or growth of mucinous or squamous tissue. Spatial tissue phenotyping indicated a
requirement of SOX9 expression for the progression of surfactant protein C-expressing progenitor cells, which gave
rise to papillary tumours. Intriguingly, while SOX9 expression was dispensable for squamous tissue formation, its loss
in fact led to enhanced squamous tumour metastasis, which was associated with altered collagen IV deposition in the
basement membrane. Our work therefore demonstrates histopathology-selective roles for SOX9 in NSCLC progres-
sion, namely as a promoter for papillary adenocarcinoma progression, but an opposing metastasis-suppressing role
in squamous histotype tissue. This attests to a pleiotropic SOX9 function, linked to the cell of origin and microenvi-
ronmental tissue contexts.
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great
Britain and Ireland.
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Introduction
Lung cancer remains the leading cause of cancer-related
mortality, the majority of which is due to non-small cell
lung cancer (NSCLC; 85%). NSCLC is subdivided into
two major histotypes, adenocarcinoma (AC) and squa-
mous cell carcinoma (SCC), of which the AC group is
the most heterogeneous [1–4]. ACs are further subdi-
vided based on the tissue’s predominant histotype struc-
ture, particularly papillary AC (PAC), mucinous AC
(MAC), and acinar AC (AAC) [5]. Certain driver muta-
tions are selectively enriched in these AC subtypes. For
example, KEAP1 mutation or NRF2 overexpression
occurs more frequently in PACs compared with total
NSCLCs, and KRAS, EGFR or ALK mutations have
been associated with mucinous, lepidic growth, or signet
ring structure, respectively [6,7]. Molecular and genetic
functions therefore need to be interpreted within these
histopathology-specific tissue contexts.
The transcription factor SOX9 is amember of the SOX
(sex-determining region Y-related) family [8] and it reg-
ulates a variety of developmental processes [9–11]. Dur-
ing lung development in the mouse, SOX9 is expressed
in a timed manner to coordinate lung branching morpho-
genesis and alveolar differentiation [12,13]. SOX9 is
silenced in adult tissues but frequently re-expressed in
cancer, where it has been associated with increased cell
proliferation, transcriptional reprogramming, and self-
renewal of stem cells, and increased cell invasiveness
and drug resistance [14–17]. The SOX9 gene resides on
the long arm of chromosome 17 (17q24.3), which is fre-
quently gained in non-smokers with lung AC [18]. In
patients, elevated SOX9 expression has been associated
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with poor survival and advanced clinical NSCLC stage,
and its expression was shown to promote the prolifera-
tion of AC cells in vitro through affecting the CDKN1A
and CDK4 cell cycle regulators [19,20]. However, while
many studies have found oncogenic roles for SOX9, sup-
porting its therapeutic targeting, the downregulation of
SOX9 has also been linked to relapse of prostate cancer
[21] and stage II colon cancer [22], indicating that
SOX9 has pleiotropic functions. Despite NSCLC consti-
tuting a heterogeneous set of diseases, the potential
histopathology-selective role of SOX9 in NSCLC pro-
gression has not been studied.
Distinct sets of developmental signals and transcrip-
tion factors are expressed in different lung progenitor
cells and thereby exert lineage-specific functions [23].
In recent years, the ways in which different cells of origin
influence NSCLC progression have been addressed by
applying genetically engineered mouse models [24].
Using adenovirus-mediated Cre recombination, we pre-
viously showed that conditional KrasG12D expression
combined with loss of Lkb1 (the official HUGO symbol
for the human gene is STK11) in CC10-expressing club
cells (CC10; the HUGO symbol for the gene is
SCGB1A1) gives rise to a wide NSCLC histotype spec-
trum encompassing minimally invasive AC (IAC),
MAC, AAC, and PAC, as well as adenosquamous carci-
noma (ASC) [25], a rare NSCLC subtype exhibiting both
SCC and AC features [26]. In contrast, in alveolar type II
(AT2) progenitors expressing surfactant protein C (SPC),
the same genetic alterations mainly lead to IAC and PAC
formation [25]. Among murine NSCLC models, these
KrasG12D;Lkb1fl/fl mice are unique in carrying a wide
spectrum of NSCLC histotypes, including the more
aggressive ASC subtype, permitting comparative study
of the putative histopathology-specific roles of SOX9
expression in NSCLC progression. We therefore estab-
lished heterozygous and homozygous conditional Sox9
null KrasG12D;Lkb1fl/fl cohorts and examined how Sox9
loss influenced the progression of lesions of distinct his-
totypes. We describe opposing histopathology-selective
roles of SOX9 in NSCLC progression and metastasis,
and link these to the cell of origin and tumour microenvi-
ronment contexts, with ramifications for future directions
in therapeutic intervention.
Materials and methods
Human and mouse tumour tissues
Breeding of KrasG12D/+;Lkb1flox/flox (KrasG12D;Lkb1fl/fl)
mice, genotyping, and lung tumour initiation by intrana-
sal infection with progenitor cell-directed Ad5-Cre
viruses were performed as described previously [23].
Sox9-defficient cohorts were generated by crossing
KrasG12D;Lkb1fl/fl and Sox9flox mice (B6.129S7-
Sox9tm2Crm/J; The Jackson Laboratory, Bar Harbor,
ME, USA). Sox9 genotypes were determined using the
supplied protocol 29713 (The Jackson Laboratory). Ani-
mal work was approved by the Experimental Animal
Committee of the University of Helsinki and the State
Provincial Office of Southern Finland
(ESAVI/6365/2019). A tissue microarray (TMA-1) was
constructed previously [27] that included human NSCLC
SCC, ASC, and PAC lesions collected from the Helsinki
Biobank’s pathology sample archive (Helsinki Biobank
project number HBP2016002). Raw data from the murine
and TMA-1 analyses are provided in supplementary mate-
rial, Tables S1 and S2. The large human adenocarcinoma
TMA collection (TMA-2; 970 samples) was obtained from
a continuous retrospective cohort of archival human lung
adenocarcinoma tissue from theUniversityHospital Leices-
ter, under research ethics committee approval. Clinicopath-
ological and follow-up data were obtained from regional
and national databases, and all morphological assessments
were performed by a subspecialty consultant diagnostic
histopathologist.
Tissue processing, immunohistochemistry (IHC),
and image acquisition
Mouse lung tumours were processed and embedded in
paraffin as reported in ref 23. FFPE tissue blocks con-
taining whole murine lung or TMA blocks were cut at
4 μm thickness. Two sequential sections were placed
on one glass slide (SUPERFROST® PLUS; Thermo
Fisher Scientific, Waltham, MA, USA) and labelled to
mark the sectioning order. Adjacent tissue sections were
each stained with one antibody.
For all antibodies except anti-SPC (which did not
require antigen retrieval), antigen retrieval was per-
formed using 10 mM sodium citrate, pH 6.0. All anti-
bodies except anti-SOX2 were incubated for 1.5 h at
room temperature, while anti-SOX2 antibody was incu-
bated overnight at 4 C.
For routine signal development, BrightVision poly-
HRP goat anti-rabbit IgG (Immunologic BV, Duiven,
The Netherlands) was incubated at room temperature
for 30 min. For developing the SOX2 signal, DaG-
HRP (sc2020; Santa Cruz Biotechnology, Dallas, TX,
USA; 1:100) was incubated at room temperature for
30 min. For signal detection, a Bright-DAB Substrate
Kit (Immunologic BV) was used. Whole slide bright-
field scans of stained tissue sections were acquired
using a 20 objective (PANNORAMIC 250 scanner;
3DHISTECH Ltd, Budapest, Hungary). Sections cut
at 3 μm from the TMA-2 human adenocarcinoma
cohort were duplex-stained using a Ventana autostainer
(Roche Diagnostics, Rotkreuz, Switzerland) with anti-
bodies for cytokeratin AE1/AE3 (# NCL-L-AE1/AE3;
Leica Biosystems, Wetzlar, Germany; 1:250) detected
with Roche DISCOVERY yellow chromogen and
SOX9 (supplementary material, Table S3) with Roche
DISCOVERY purple chromogen. The primary anti-
bodies used for mouse samples, TMA-1 are sum-
marised in supplementary material, Table S3. Up to
three 1-mm cores per tumour were analysed. Images
of haematoxylin-counterstained images were acquired
using a Hamamatsu nanozoomer (Hamamatsu Photon-
ics, Shizuoka, Japan).
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Region-of-interest (ROI)-specific image analysis
Histopathology classification of murine tumours was
performed in conjunction with an expert pathologist as
in refs 23 and 24. The sizes of individual tumours and
lung tissues were measured using a Pannoramic Case-
Viewer (3DHISTECH Ltd). For image analysis, TIFF
images of murine lungs with haematoxylin and eosin
(H&E) and biomarker staining were exported at a mag-
nification of 1:2. Individual tumours on H&E-stained
images were then outlined and annotated by their histo-
types using ImageJ/Fiji [28] (‘Analyze’!‘Tools’
!‘ROI manager’) to generate an ROI library for each
murine sample. Images of serial sections stained for
SOX9, Ki-67, pAKT, and pERK were registered with
the nearby H&E images using our previously reported
open-source software Spa-R [29]. For quantifying Ki-
67 and SOX9-positive nuclei, individual tumour images
were exported as inverted 8-bit grayscale images and
processed with a CellProfiler pipeline [30] built with
nuclei segmentation, intensity measurement, threshold-
based filtration, and percentage calculation modules.
The parameters in the pipeline were specified for each
staining. To measure pERK and pAKT staining in indi-
vidual tumours, a workflow using Spa-R and ImageJ/
Fiji, and thresholds decided by three independent immu-
nohistochemistry experts, were implemented as before
[29]. All raw results can be found in supplementary
material, Table S1. To mark collagen IV fibres with red
pseudo-colour, our in-house open-source Spa-Q soft-
ware [29] was applied, using identical thresholds for all
samples.
Image analysis of the NSCLC cohort (TMA-1) and the
adenocarcinoma cohort (TMA-2)
In both TMA-1 and TMA-2, tumour cell nuclei were
categorised as negative, weak, moderate, or strong for
SOX9 staining by the same expert pathologist, and an
H-score was calculated for each core (% weak + 2 %
moderate + 3 % strong nuclei, yielding a score from
0 to 300). The SOX9 expression cut-off, which defined
‘SOX9-low’ and ‘SOX9-high’ categories for TMA-2
survival and proliferation analyses, was generated using
the Contal and O’Quigley method [31]. This cut-off
value corresponded to the most significant difference in
the survival curves between the two groups and was
the one that provides the minimum P value among all
potential cut-off values. The same cut-off was used in
all the analyses. Ki-67 staining analysis on TMA-2 was
performed with the Ventana pre-diluted ready-to-use
kit and assessed by a trained histopathologist.
Statistical analyses
Statistical comparisons and data visualisation for clinical
samples (TMA-1) and murine samples were performed
using GraphPad Prism 8, where one-way ANOVA mul-
tiple comparison (Kruskal–Wallis test, non-parametric
test), unpaired t-test (non-parametric Mann–Whitney
test), or Fisher’s exact test was used. Statistical
significance of survival was assessed with a log-rank
(Mantel–Cox) test. P values less than 0.05 were consid-
ered significant. For TMA-2, statistical analyses were
performed in R (version 4.0.4). The Cox proportional
hazard model was built through the survival package,
and the Kaplan–Meier curves were produced with the
survminer R package (https://CRAN.R-project.org/
package=survminer), which was also used to generate
the log–log plots for testing the proportional hazards
assumption.
Results
The correlation between SOX9 expression and NSCLC
staging is histopathology-selective
To evaluate SOX9 expression in NSCLC histotypes
according to their stages, we performed IHC analyses of
TMAs encompassing 28 human lung SCCs, 13 human
lung ASCs, and 25 human lung PACs. SOX9 expression
was not seen in normal lung tissues but was observed in
the tumour regions in most of the samples (SCC: 96%;
ASC: 100%; PAC: 88%). This significantly contrasts with
the expression of SOX2, a well-established genetic driver
of SCC, which wasmore commonly detected in SCCs and
ASCs than in PACs (SCC: 85%; ASC: 100%; PAC: 8%)
(supplementary material, Figure S1A). The SOX9 protein
was mainly located in the nucleoplasm, but cytoplasmic/
membranous expression was also observed, particularly
in PACs (Figure 1A).
Based on visual scoring, we assigned tumour nuclei to
‘SOX9-negative’, ‘SOX9-weak’, ‘SOX9-moderate’ or
‘SOX9-high’ categories, and calculated H-scores to
quantify the relative SOX9 expression level of each sam-
ple. The samples were then grouped by their clinical
stages (Figure 1B). Among the three NSCLC histotypes,
PACs showed a tendency towards a positive correlation
between SOX9 expression and clinical stage (grouped
by stages I & II and stages III & IV, p = 0.041). In con-
trast, ASCs and SCCs frequently showed high SOX9
expression also in the low-stage tumours.
To more deeply explore the relationship between
SOX9 and the phenotype of human lung adenocarci-
noma, we quantified the expression of SOX9 expression
in epithelial tumour cell nuclei in a large cohort of
970 resected primary lung adenocarcinomas in tissue
microarrays (supplementary material, Figure S1B). Cor-
roborating previous studies [19,20,32], epithelial tumour
cell proliferation assessed by the percentage of
tumour nuclei expressing Ki-67 was significantly related
to SOX9 expression (p = 0.003), and in analysis of
patient survival time after surgery, higher median levels
of SOX9 were related to relatively poor outcome (Cox
model HR = 1.2, p = 0.044) (supplementary material,
Figure S1C,D). Interestingly, nuclear SOX9 levels were
higher in mucinous than in non-mucinous tumours
(p < 0.001) (supplementary material, Figure S1C), and
cores with invasive growth patterns showed a non-
significant trend towards higher levels of SOX9
18 J Bao et al
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd.
on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2021; 255: 16–29
www.thejournalofpathology.com
expression selectively in non-mucinous samples
(p = 0.09 in non-mucinous; p = 0.58 in mucinous)
(Figure 1C). Finally, a higher median level of SOX9
was related to relatively poor outcome in patients with
non-mucinous but not with mucinous AC (p = 0.028
in non-mucinous; p = 0.8 in mucinous) (Figure 1D).
This therefore tentatively suggested a non-mucinous
AC histotype-selective impact of SOX9 expression on
tumour invasiveness and patient survival.
SOX9 is commonly expressed in advanced murine
KrasG12D;Lkb1fl/fl tumours
We subsequently applied animal models to study the role
of SOX9 in NSCLC histotype formation. As a first step,
we examined SOX9 expression in tumours from
KrasG12D;Lkb1fl/fl mice (KL mice characterised in ref
25 and in this study named KLSwt). Most KLSwt histo-
types, including ASC, MAC, and PAC, displayed high
Figure 1. Histopathology-selective correlation between SOX9 expression and NSCLC progression. (A) Representative images illustrating SOX9
expression in normal and malignant epithelial lung tissues. Scale bar: 20 μm. (B) Dot plot showing SOX9 expression (assessed as H-scores) in
SCC, ASC, and PAC NSCLC subtypes, grouped as stage I& II and stage III& IV, with staging categories determined following American Joint
Committee on Cancer (AJCC) criteria. Each dot represents one sample. Statistical significance was assessed with unpaired t-test (non-
parametric Mann–Whitney test): *p = 0.041. (C) Dot plot showing the relationship between SOX9 and mucinous phenotype and local inva-
siveness. (D) Cox proportional hazards model of survival after surgery in patients with non-mucinous AC (left) and mucinous AC (right) related
to SOX9 expression. Higher median nuclear SOX9 expression is significantly associated with relatively poor overall survival in patients with
non-mucinous lung AC after surgery.
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SOX9 expression, but its expression was fully absent or
low in IACs, which are small and represent the least
aggressive lesion type with low proliferation and onco-
genic signalling activities (Figure 2 and supplementary
material, Figure S2A). Therefore, SOX9 expression
levels in murine NSCLC histotypes were comparable to
those in clinical NSCLC, showing absent or low expres-
sion in IAC or in situ non-mucinous adenocarcinomas
and wide expression across all advanced NSCLC
histotypes.
SOX9 expression is essential for papillary structure
formation in KrasG12D;Lkb1fl/fl murine tumours
To investigate the impact of Sox9 loss on histotype forma-
tion, we established Sox9-deficient KrasG12D;Lkb1fl/fl
Figure 2. SOX9 expression is highest in advanced KrasG12D;Lkb1fl/fl;SOX9+/+ murine NSCLC tumours. (A) Scatter dot plot showing SOX9
expression in individual tumours, grouped by histotype and calculated as percentages of SOX9-postive cells in total number of tumour cells,
from six KLSwt-CC10 and eight KLSwt-SPC mice. Statistical significance was assessed with one-way ANOVA (non-parametric Kruskal–Wallis
test): *p < 0.05; ****p < 0.0001. (B) Representative H&E and SOX9 staining illustrating SOX9 expression in each histotype. Areas depicted at
greater magnification are outlined with black squares in the H&E images. Red dashed lines outline a PAC, MAC, or separate SCC and AC
regions within an ASC; the black dashed line outlines an IAC. Scale bars: 500 μm for original; 10 μm for magnified images.
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cohorts, including KLShet (losing one floxed Sox9 allele)
andKLSnull (losing two floxed alleles), following infection
with either Ad5-CC10-Cre or Ad5-SPC-Cre viruses
(Figure 3A).
Kaplan–Meier survival analysis showed significantly
longer survival of KLShet-SPC and KLSnull-SPC mice,
as well as KLSnull-CC10 mice, compared with the rela-
tive KLSwt controls (Figure 3B). The increased life span
Figure 3 Legend on next page.
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of KLShet-SPC and KLSnull-SPC cohorts corresponded
to a reduced PAC burden, and no papillary tissue struc-
ture was observed in SOX9-negative tumours in these
mice (Figure 3C). Notably, recombination escape is
known to arise in three-allelic compound mice [33],
and SOX9-positive tumours were indeed observed at a
recombination escape rate of around 30% (Figure 3C
and supplementary material, Figure S3A,C and
Table S1). Interestingly, these SOX9-positive tumours
in the KLSnull-SPC cohort always showed a papillary tis-
sue structure. On the other hand, the growth of smaller,
less proliferative, and minimally invasive IACs (evi-
denced by lack of nuclear high mobility group AT-hook
2, or HMGA2, expression) was not affected by Sox9 loss
(Figure 3C and supplementary material, Figure S2A,B).
In Ad5-CC10-Cre cohorts, Sox9 loss was associated
with a shift in the major tumour burden from ASC to
SCC tissue with large necrotic regions (Figure 3D).
These SCC tumours were positive for the AC marker
NKX2-1, lacked SOX2 expression, and strongly
expressed nuclear HMGA2 (supplementary material,
Figure S2B). This staining profile matched those of
ASCs in the KLSwt-CC10 cohort, suggesting that SCC
tumours derived from ASCs; we hence called these
‘SCC-like’ from here onwards. Interestingly, only the
formation of ASC with papillary AC cores, but not that
with mucinous AC cores, was disrupted (Figure 3D).
Additionally, PAC was the only AC subtype normally
present in KLSwt-CC10 mice that was absent following
Sox9 loss. Again, SOX9-positive lesions (ASC with
papillary AC cores or PACs) were observed in the
KLSnull-CC10 cohort, here at a recombination escape
rate of around 9% (Figure 3D and supplementary mate-
rial, Figure S3B,D and Table S1).
Taken together, these data suggested that SOX9 expres-
sionwas selectively required for the growth of papillary his-
totype tissue. In support of this conclusion, SOX9-positive
tumours in both the Sox9null-SPC and the Sox9null-CC10
cohorts, resulting from Sox9 recombination escape, always
showed a papillary tissue structure (supplementarymaterial,
Figure S3). As expected, based on the obligate role of
LKB1 as a tumour suppressor in this model, we found no
evidence for escape of Lkb1 recombination (IHC staining;
data not shown). Importantly, in both the CC10-infected
and the SPC-infected cohorts, KLShet resembled KLSnull
mice in terms of survival, histopathology spectra, and
tumour burden (Figure 3B–D and supplementary material,
Figure S3C,D), together indicating that both heterozygous
and homozygous Sox9 loss selectively disrupted papillary
NSCLC histotype formation.
SOX9 expression is essential for the oncogenic
transformation of cancer-initiating SPC+ cells
To understand why SOX9 selectively regulated the for-
mation of papillary tissue structure, we studied the spa-
tial expression of cell lineage markers and SOX9 in
different tumour histotypes. In the Ad5-SPC-Cre
cohorts, SPC, whichmarks AT2 progenitor cells and dif-
ferentiated AT2 cells, was highly expressed in IACs,
while SPC was absent or expressed at low levels in
PACs (Figure 4A,B). Also in the Ad5-CC10-Cre
cohorts, IACs were positive for SPC, whereas PACs
and papillary AC cores of ASCs showed negative to
low SPC expression (Figure 4C,D and supplementary
material, Figure S4A), indicating that also CC10-Cre
induced the transformation of SPC+ cells. Other tumour
histotypes found in Ad5-CC10-Cre cohorts that were not
affected by Sox9 loss (Figure 3D), particularly mucinous
and squamous tissue, were always SPC-negative
(Figure 4D and supplementary material, Figure S4A).
Interestingly, we further found that SPC expression
was mutually exclusive with SOX9 expression in PACs
as well as papillary AC cores of larger ASC tumours, and
marked tumour subregions that lacked a prominent pap-
illary structure (Figure 4B,D). The concomitant appear-
ance of papillary structure together with SPC loss upon
SOX9 expression, together with the absence of PAC
and papillary AC cores following Sox9 loss as shown
in the section above, suggested that SOX9 promotes
tumour progression from SPC+ progenitor cells, result-
ing in papillary tissue formation in the KL NSCLC
model (illustrated in Figure 4E).
SOX9 expression differently regulates AC and SCC
tissue metastases
Given the previous links between SOX9 expression and
invasion, we next asked how Sox9 loss affected the met-
astatic potential of NSCLC histotypes by analysing the
mediastinal lymph nodes (supplementary material,
Figure S4B,C). Metastases in KLSwt-SPC (observed in
Figure 3. Sox9 loss disrupts the formation of papillary histotype tissue in KrasG12D;Lkb1fl/fl NSCLC tumours. (A) Murine Sox9 loss-of-function
and control cohorts established for this study. (B) Kaplan–Meier survival curves for the indicated cohorts. Statistical significance was assessed
with log-rank (Mantel–Cox) test: *p < 0.05, **p < 0.01. (C) Left: representative images illustrating whole lung sections of individual mice
from the indicated Ad5-SPC-Cre cohorts, depicting H&E staining and corresponding SOX9 expression. Scale bars: 1000 μm. Right: bar chart
showing the histotype-selective tumour burden (% total histotype-specific tumour region per lung) in the indicated cohorts. Numbers of mice
that carry the specified histotype are listed above each bar. All tumours were plotted; PACs found in the KLSnull-SPC cohort were due to Sox9
recombination escape. A plot depicting the data of all tumours per individual mouse can be found in supplementary material,
Figure S3C. Statistical significance was assessed with one-way ANOVA and non-parametric Kruskal–Wallis test: *p < 0.05, ***p < 0.001.
(D) Left: representative images illustrating whole lung sections of individual mice from the indicated Ad5-CC10-Cre cohorts, depicting
H&E staining and corresponding SOX9 expression. Scale bars: 1000 μm. Right: bar chart showing the histotype-selective tumour burden
(% total histotype-specified tumour region per lung) in the indicated cohorts. Numbers of mice that carry the specified histotype are listed
above each bar. All tumours were plotted; PACs and ASCs with papillary AC cores found in the KLSnull-CC10 cohort expressed SOX9, indicating
recombination escape. A plot depicting all tumours per individual mouse can be found in the supplementary material, Figure S3D.
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3/8 KLSwt-SPC mice) were similar to those described
previously [32] and represented AC histotype tissue with
papillary structure (supplementarymaterial, Figure S4C).
Metastases that eventually developed in KLSnull-SPC
mice (4/19 mice, including two minimal metastases)
were always SOX9-positive, suggesting that they had
Figure 4 Legend on next page.
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originated from PACs that had escaped Sox9 recombina-
tion (Figure 5A,C). Also, the KLShet-SPC mice devel-
oped frequent metastasis (12/17 mice, including six
minimal metastases), which could not, however, be
linked to SOX9 status due to the heterozygous SOX9
expression. Importantly, as reported previously [32],
squamous metastases were never detected in KLSwt-
CC10 mice but were observed in 2/11 KLShet-CC10
and 2/13 KLSnull-CC10 mice (Figure 5B,D and supple-
mentary material, Figure S4D). Three of the four mice
carrying squamous metastases succumbed to their dis-
ease relatively early and within the survival range of con-
trol KLSwt mice. This analysis therefore suggested an
overall reduction in AC metastases following Sox9 loss,
linked to a block in PAC progression, mirrored by a nota-
ble increase in SCC-like metastases following Sox9 loss
in murine NSCLC.
As SOX9 is known to regulate extracellular matrix
(ECM) deposition, we next examined ECM features fol-
lowing Sox9 loss by staining of collagen IV (COLIV), a
central component of the tumour basement membrane.
COLIV was expressed in both IAC and PAC but only
in the latter did it form a linear structure, which was also
observed in papillary SOX9-expressing tissue at meta-
static sites (Figure 6A,B). This suggested that a precise
alignment of COLIV, regulated by SOX9 expression,
accompanied the actual growth and later invasiveness
of PACs. On the other hand, in Sox9wt ASCs, COLIV
formed continuous boundaries around squamous tumour
cell pockets (Figure 6C), while Sox9null SCC-like
tumours and the SCC regions of ASCs with mucinous
AC cores showed thinner parallel COLIV fibres as well
as granular and focal depositions (Figure 6D). A similar
alteration in COLIV rearrangement was also observed in
the SCC-like LN metastases (Figure 6D). Taken
together, in murine PACs, Sox9 loss reduced primary
papillary tumour progression and consequently their
invasion, possibly related to an alteration in ECM depo-
sition, while in the squamous histotype the altered
COLIV deposition following Sox9 loss in fact was asso-
ciated with an increase in tumour invasiveness and
metastasis (illustrated in Figure 6E).
Discussion
Re-expression of the lung developmental transcription
factor SOX9 specifically in malignant lung tissues, in
conjunction with the reported positive correlation of
SOX9 expression levels with clinical NSCLC staging,
renders SOX9 a good candidate for prognostic and ther-
apeutic interrogation. We studied here the previously
unexplored expression and role of SOX9 in NSCLC his-
totypes. We identified a trend towards elevated SOX9
expression in non-mucinous clinical invasive AC com-
pared with in situ samples, as well as in murine PAC
compared with IAC, with IAC constituting an early form
of PAC. SOX9 was widely expressed across multiple
invasive stage murine and clinical NSCLC histotypes,
yet murine Sox9 loss only affected papillary structure
formation, not the initiation or progression of other his-
totype lesions. The overarching conclusion of our work
is therefore that the role of SOX9 in NSCLC is to be
interpreted in a histotype-selective manner.
The expression of KrasG12D combined with Lkb1 loss
in alveolar AT2 or bronchial club lung progenitor cells
gives rise to a range of NSCLC histotype tumours.While
the alveolar differentiation marker SPC was uniformly
expressed in SOX9-negative IAC, its downregulation
coincided with the appearance of a papillary tissue struc-
ture, and SPC was completely absent in mature
SOX9-positive papillary tumour regions. A transition
from alveolar de-differentiation to gradual SOX9
expression was similarly seen following oncogenic
KRAS expression in organoids [34] and corroborates
data showing that ectopic expression of SOX9 in embry-
onic lungs prevented AT2 cell differentiation [12,13].
This indicates that activation of the KRAS–SOX9 axis
is intrinsically associated with AT2 lineage exit, sugges-
tive of an overall model in which cancer development
may resemble a reverse process of normal lung tissue
development. Use of a conditional Sox9null model to
address the role of SOX9 in NSCLC progression showed
that Sox9 loss disrupted the formation of PAC and papil-
lary AC cores of ASC lesions but not IAC or histotypes
derived from bronchial progenitors. This therefore
Figure 4. SOX9 expression drives the oncogenic transformation of SPC+ progenitors. (A) Representative images illustrating SOX9 and SPC
staining in the lung of a KLSwt-SPC and a KLSnull-SPC mouse. More IACs were observed in the KLSnull-SPC mouse, which all expressed
SPC. Scale bars: 1000 μm. (B) Upper: representative images of a tumour from a KLSnull-SPC mouse that had partially escaped Sox9 recom-
bination. The papillary area outlined by the red dashed line contained SOX9-positive regions that were SPC-negative; the remaining IAC-like
region was SPC-positive. Lower: representative images of a PAC from a KLSwt mouse depicting mutual exclusive expression of SOX9 and SPC.
Scale bars: 100 μm. (C) Representative images illustrating SOX9 and SPC staining in the lung of a KLSwt-CC10 and a KLSnull-CC10 mouse,
where IACs were SPC-negative. Scale bars: 1000 μm. (D) Representative images showing spatial SOX9 and SPC expression in tumours of
the indicated histotypes detected in KLSwt-CC10 mice. The red dashed line separates the SCC and AC regions within an ASC tumour. Scale
bars: 100 μm. (E) Schematic explaining how SOX9 regulates murine NSCLC progression in a histotype-selective manner. Left: in KLSwt mice,
SPC+ AT2 cells, targeted by Ad5-SPC-Cre virus, give rise to SPC+ IACs. These IAC lesions gradually start to express SOX9, and this is essential
for papillary tumour progression; the SPC+ identity is gradually lost when papillary tissue structure appears. Upon Ad5-CC10-Cre infection,
SPC+ IACs again develop, either from AT2 cells that are targeted by the CC10-Cre virus or from trans-differentiated club or dual positive
SPC+/CC10+ cells. SOX9 expression in papillary tissue corresponds with loss of SPC expression, giving rise to PACs or the papillary AC core
of ASC. Lastly, transformation of CC10+ progenitor cells, which are mostly Clara cells, gives rise to MAC, AAC, and ASC with mucinous AC
core. Right: Sox9 loss selectively disrupts papillary histotype tissue formation in which transformed cells exhibit progression from an SPC-
positive to an SPC-negative status.
24 J Bao et al
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd.
on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2021; 255: 16–29
www.thejournalofpathology.com
suggests that SOX9 expression is specifically required to
drive the progression of lesions developed from an
SPC+ cell of origin. Precisely how SOX9 drives AT2
lineage exit remains unclear, and an intriguing future
direction would hence be to identify the lineage-specific
SOX9 transcriptional network, and particularly its inter-
play with transcription factors known to regulate alveo-
lar differentiation, such as FOXA2 [20,35,36]. Our
study thus reveals a role of SOX9 in NSCLC progression
that is selectively linked to the SPC+/AT2 lineage of
cancer-initiating lung progenitor cells.
We showed that Sox9 loss decreased AC metastasis,
which is consistent with a reported pro-metastatic role
of SOX9 in multiple cancer types [37–39]. But surpris-
ingly, the incidence of SCCmetastasis increased follow-
ing Sox9 loss. One mechanism in which SOX9 is
Figure 5. SOX9 expression differently regulates AC and SCCmetastases. (A) Bar chart illustrating the proportion of total animals exhibiting no
metastasis, minimal metastasis, or overt metastasis in the mediastinal lymph nodes (LNs) in the indicated Ad5-SPC-Cre cohorts. Total num-
bers of mice are shown above each bar. Metastases were all SOX9-positive, and all were adenocarcinoma. (B) Bar chart illustrating the pro-
portion of total animals exhibiting no, minimal, or overt metastasis in the mediastinal LNs, subgrouped by SOX9 status, in the indicated
Ad5-CC10-Cre cohorts. Total numbers of mice are shown above the bars. (C) Representative images illustrating minimal metastasis (only
a small LN region infiltrated with tumour cells) and overt metastasis (LN structure severely disrupted) in Ad5-SPC-Cre cohorts; NKX2-1 indi-
cates AC histotype tissue. Areas depicted at greater magnification are outlined with black squares. Scale bars: 500 μm for original images;
100 μm for magnified images. (D) Representative images illustrating SCC-like metastases in Ad5-CC10-Cre cohorts; p63 indicates SCC his-
totype tissue. Areas depicted at greater magnification are outlined with black squares. Scale bars: 500 μm for original images; 100 μm for
magnified images.
Histopathology-selective roles of SOX9 in lung cancer progression 25
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd.
on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2021; 255: 16–29
www.thejournalofpathology.com
involved in tumour metastasis is through regulating the
expression and deposition of ECM components, includ-
ing multiple collagens and laminins [14]. Our findings
importantly suggest that ECM rearrangements regulated
by SOX9 expression may influence tumour invasiveness
in different and microenvironmental context-dependent
Figure 6 Legend on next page.
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manners. We identified differential COLIV deposition,
which marks tumour basement membranes, across
NSCLC histotypes. Linear COLIV was observed in
SOX9-expressing primary PACs and papillary meta-
static LNs but not in non-metastatic SOX9-negative
IACs, suggesting that it is part of a supportive structure
for papillary growth and metastasis upon SOX9 expres-
sion. On the other hand, in the SOX9-expressing squa-
mous regions, COLIV formed pocket structures
surrounding the tumour islets, and these became discon-
tinuous and granular in the SOX-negative squamous
region. Similar COLIV discontinuity has been previ-
ously linked to the progression of oral SCC [40], sug-
gesting that disrupted squamous pocket structure is
commonly associated with increased squamous inva-
siveness. Our study therefore depicts functional hetero-
geneity of SOX9 in NSCLC metastasis, namely a
requirement for SOX9-associated matrix deposition in
papillary histotype metastasis but an opposing
metastasis-suppressing function in squamous histotype
tissue.
Analysis of Sox9 heterozygous null mice showed that
loss of one Sox9 allele already disrupted papillary tissue
formation. While Sox9 haploinsufficiency has not been
previously described in cancer studies, loss of one
Sox9 allele has been associated with defects in beta-cell
development during murine pancreas organogenesis
[41], as well as with defects in murine chondrocyte dif-
ferentiation [42]. In humans, Sox9 haploinsufficiency
caused by de novo heterozygous Sox9 mutation leads
to a rare but severe form of skeletal dysplasia called cam-
pomelic dysplasia (CD) [43], and CD mutations can act
in a dominant negative manner by disrupting the capac-
ity of SOX9 to dimerise [44]. While our study demon-
strates a similar allelic dosage effect of Sox9 in
regulating NSCLC progression and metastasis, further
studies are needed to understand whether this is associ-
ated with defective SOX9 dimerisation, and which are
the target genes that essentially regulate histotype-
selective effects during NSCLC progression.
Targeting transcription factors in cancer has been a
long-standing challenge, yet the tumour cell-specific
SOX9 expression renders it an attractive therapeutic
target in NSCLC, in particular for ACs with co-
occurring KRAS and LKB1 (STK11) mutations, which
show low expression of programmed death-ligand
1 and demonstrate poor response towards checkpoint-
based immunotherapy [45–48]. Our results indicate that
the inhibition of SOX9 could hamper the progression of
early-stage ACs with SPC+/AT2 identity. Further study
should address the effect of Sox9 loss subsequent to PAC
formation, for example using a flippase-FRT and Cre-
loxP dual-recombinase system [49], to learn whether
SOX9 is similarly required for the progression or metas-
tasis of already established PACs. If so, then this would
provide additional support favouring the development of
SOX9 inhibitors to treat advanced AC that derived from
AT2 progenitors, particularly in the context of co-
occurring KRAS and LKB1 (STK11) mutations. Small
molecules that disrupt the protein-interaction function
of the SOX18 vascular development regulator have
recently become available [50]. A similar strategy could
possibly be applied to identify small molecules that dis-
rupt SOX9 dimerisation or its binding to other lineage-
specific transcription factors. However, while our study
implicates SOX9 as a potential anti-cancer target in pap-
illary histotype NSCLC from AT2 cell of origin, Sox9
loss was also associated with enhanced squamous tissue
metastasis, emphasising that therapeutic considerations
ought to consider the tumour’s histotype context and
cannot simply adopt SOX9 positivity as a biomarker
for response.
In conclusion, we demonstrate opposing requirements
for SOX9 in different NSCLC histotypes and shine light
on a pleiotropic SOX9 function that links to different
tumour progenitor cells and extracellular microenviron-
mental features. This provides a strong motivation to
evaluate the prognostic value and therapeutic application
of SOX9 in the context of NSCLC histopathology types.
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